COVID-19 Pharmacy Updates

June 26, 2020

Should I be concerned about the recent media coverage on the increase in opioid-related deaths and correlation to COVID-19?

Yes. The nation is focused on the COVID-19 pandemic, but the opioid epidemic remains in full force. The American Medical Association (AMA) reports that more than 30 states have had increases in opioid-related deaths, in correlation with the COVID pandemic. Early data has demonstrated that the stress from unemployment and economic hardship and the prolonged periods of social distancing, and overall uncertainty of COVID-19 have caused an increase in opioid-related mortality. Depression and anxiety are risk factors for addictions. For those with opioid addiction, access to medications is important. This is where we may see a ripple effect and impact in LTC facilities. As we are focused on infection control practices in our buildings during the pandemic, it is imperative to also remain diligent around controlled medication accountability to prevent diversion. A sample of some of the areas you should continue to monitor are:

  • Continue controlled medication reconciliation processes
  • Ensure consistency with storing documents, including delivery receipts
  • Observe and audit shift count process
  • Ensure Fentanyl patch placement is documented on the MAR and checked each shift
  • Check PRN documentation on the MAR matches the controlled medication inventory sheets documentation
  • Check security and access of medications awaiting disposal
  • Dispose of unused and discontinued medications as frequently as possible
  • Ensure access to all controlled medications is limited and secure

Your Consonus Nurses and Pharmacists are a trusted resource to advise around pain management or systems and monitoring to keep your residents and staff safe. Please reach out to your consultant with any questions.


June 19, 2020

Hydroxychloroquine for COVID-19 Treatment

Information around COVID-19 is quickly evolving. That includes recommendations for potential treatment options. Within a one-month period, The Food and Drug Administration (FDA) authorized emergency use hydroxychloroquine from the Strategic National Stockpile, and then cautioned against use outside of a hospital or clinical trial due to arrhythmias and now the emergency use authorization is revoked. The FDA concluded after continued review of the scientific evidence that hydroxychloroquine sulfate and chloroquine phosphate are unlikely to be effective in treating COVID-19. Additionally, in light of ongoing serious cardiac adverse events and other serious side effects, the known potential benefits of the medications no longer outweigh the known and potential risks.  Chloroquine and hydroxychloroquine are both FDA-approved to treat or prevent malaria. Hydroxychloroquine is also approved to treat autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis. Both drugs have been prescribed for years to help patients with these debilitating, or even deadly, diseases, and FDA has determined that these drugs are safe and effective when used for these diseases in accordance with their FDA-approved labeling.

Your Consonus pharmacists are drug experts and a great resource to keep you updated on the status of treatments being studied for COVID-19 patients.


June 12, 2020

Vaccines During a Pandemic

A safe and effective vaccine may be the best way to prevent COVID-19 transmission and infection. To date, no vaccine has been approved by the FDA, but more than 100 vaccines are in development globally and a few are being studied in humans after positive results in animals. Vaccines undergo a rigorous review of laboratory and clinical data to ensure the safety and effectiveness of these products. The FDA is expediting clinical trials for vaccines and scaling up of manufacturing capacity for high priority vaccines for COVID-19. A commercially available vaccine will likely not be available until 2021.

It is important to keep other immunizations on track during COVID-19. Vaccination is critical for some vulnerable patients, such as adults over 65, immunocompromised, children under 2, etc.  Data is already suggesting a drop in vaccination rates in kids. This is raising concerns about disease outbreaks, such as measles or mumps, on top of COVID-19.  The pandemic alone doesn’t change which vaccines you should or shouldn’t give. It is important to follow the usual CDC vaccine recommendations and for the vulnerable seniors we care for, ensure they are on schedule for vaccine needs, such as pneumococcal, Shingrix and influenza, as flu season approaches. 

Stay up-to-date on vaccines with these additional resources:


June 5, 2020

Consonus Pharmacy Provides Partnership During COVID-19 Crisis

The COVID-19 pandemic has tested the senior care industry in ways we would have never imagined. There’s no playbook for these unprecedented times. As a provider, you may need to lean on your ancillary partners more than normal and attributes that may not have been important in the past are now more important than ever. 

If you are a Consonus customer, you know that we’ve kept consistent pricing, provided consistent communication and education, and demonstrated resilience, among other things during this challenging time. We believe in being a partner and not just another vendor.

If you are not a current Consonus customer, we encourage you to evaluate your ancillary providers to determine the level of partnership they have provided during these trying times.

View Ancillary Provider Scorecard


May 22, 2020

Consonus Pharmacy Reopening Plans

  • Consonus Pharmacy’s reopening plan will be coordinated in conjunction with CMS’s Phase III. 
  • The plan will follow CDC and state guidance and will factor in consideration of your corporate and facility protocols.
  • Consonus pharmacy modified operations to meet the CDC and CMS restrictions under Covid 19 while helping to maintain your compliance with CMS Rules of Participation.
  • Modifications included
    • pharmacist medication regimen reviews via remote health record access
    • education programming and QAPI attendance via web conference
    • and nurse consultation via electronic health record checks and online conferencing
    • delivery via disposable packaging and no touch protocols
  • We have a listing of considerations for prioritization of any onsite consultation when the time is right and look forward to working with you in partnership as you formulate your reopening plans.


May 15, 2020

Education resources for improving resident depression and anxiety symptoms for our residents living with dementia

The COVID-19 pandemic has brought many changes to how we live our lives.  For our residents, the altered daily routines, uncertainty and social isolation, can lead to stress, fear, sadness and loneliness. Mental health disorders, including anxiety and depression, can worsen. For those living with dementia, it may even be harder to cope as they may or may not be able to fully comprehend the reasoning behind all the changes. Individuals living with dementia are therefore at a greatly increased risk for depression and anxiety due to isolation and changes in daily routine they have been experiencing.  Recognizing changes that may signal symptoms of a mood or emotional disorder is vital in providing the best possible care and responding effectively. 

Consonus pharmacy is committed to providing resources and education for our Memory Care communities.  We believe in the philosophy of Teepa Snow’s Positive Approach to Care and the goal to provide a positive dementia care culture. We have consultants who are certified trainers for Teepa Snow’s Positive Approach® to Care (PAC) and educate on dementia related awareness and provide knowledge and skill development in group settings. Please reach out to your consultant if you are interested in resources or education around this topic.

We are pleased to announce that Teepa Snow is presenting a live webinar on to help providers recognize and respond more accurately to depression and anxiety to reduce the chances for escalation and ‘non-helpful’ hospitalizations. This is a free event for all on May 28th from 12:00-1:00 PM PST.  

Click here to register. 


May 7, 2020

We understand this can be a challenging time and the last thing we want is for a resident to worry about receiving and managing their medications. We’re outlining 5 ways Consonus Pharmacy can help minimize disruptions and maintain medication safety. 

Q:   How do I assist in getting a resident switched to Consonus Pharmacy?

A:  There are three simple steps to sign a resident up with Consonus Pharmacy Services:

  1. Resident or responsible party to sign Consonus Agreement form.
  2. Gather face sheet, updated prescription insurance information and medication list. Please indicate medications not to be filled and sent.
  3. Fax information to Consonus Pharmacy.

Q:  Can I get emergency medications for a resident that does not use Consonus Pharmacy as their preferred pharmacy?

A: Our biggest priority is the safety of each resident. As your contracted partner pharmacy, we will do everything possible to send emergency supplies, if needed. This is a unique situation that we all must work together to problem solve. Please call Consonus Pharmacy to discuss the individual situation.


Q:  The family is unable to bring the medications into the community for their loved one. Can Consonus help?

A:  We realize that families will be facing their own challenges related to COVID-19, making managing medications for their loved one more complicated. Options in this case would be to sign the resident up to utilize Consonus as their preferred pharmacy or contact us to arrange emergency supply of medications.


Q:  Does Consonus charge for emergency fills for residents that do not use Consonus?

A:  Because taking care of seniors is the most important thing to Consonus, we are waiving all emergency delivery charges for non-Consonus residents during the COVID-19 pandemic.

Q:  Will Consonus dispense over the counter medications for a resident that does not use Consonus as their primary pharmacy?

A:  Like any other medication, we will dispense in bubble pack systems, which are resident specific and in standardized packaging that the community is accustomed to. Standard packaging and systems decrease the risk for medication errors. 


May 1, 2020

Consonus Pharmacy Consultants Update

As CMS allowed only nominal waivers to the Rules of Participation, how have the pharmacy consultants adapted services to maintain regulatory requirements and meet facility and community needs?

The Consonus Pharmacy consulting team adapted quickly to innovate ways of working within the COVID-19 restrictions. We are pleased to announce through leveraging of technology and remote resources that there were no delays in scheduled visits by the nurse and pharmacist teams. Not only are our nurse and pharmacist consultants helping customers navigate COVID-19 issues that may arise, but also, we are continuing to monitor the safety and compliance of existing systems.

Here are just a few ways that Consonus Pharmacy consultants have quickly adapted and are monitoring remotely:

  • Infection Prevention:
    • COVID positive individualized and emergency medication storage planning to reduce infection potential and preserve PPE.
    • Prompt provision of infection control policies and procedures, coupled with education for focused surveys.
  • Preservation of PPE:
    • Evaluations to consolidate medication passes where able.
    • Pharmacist assessment for temporary suspension of medications / ointments to decrease direct contact and preserve PPE.
  • PDPM Programming:
    • Continuation of early pharmacist intervention on all admissions (aMRRs) to protect patient safety and financial implications for skilled nursing clients.
  • Controlled Substance Programming:
    • Controlled medication accountability reports developed.
    • Emergency supply monitoring.
    • State waiver assistance for virtual drug destruction.
  • QAPI Meetings, Medication Regimen Reviews and Inservices:
    • Interdisciplinary Team (IDT) meetings: Psychoactive / QAPI via virtual communications held on time and in compliance with your CMS mandates.
    • Education and training provided routinely via remote presentation.
    • Resident-centered pharmacist reviews to optimize medication regimens.

During these times, it is important to not only deal with the task at hand, but also to maintain your systems and compliance. Please contact your nurse or pharmacist consultants if you need assistance. We are available to help you meet your immediate and long term clinical and compliance goals.


April 30, 2020

Remdesivir use for COVID-19

Dr. Fauci says Remdesivir is a “very important first step” in fighting coronavirus and will set a new “standard of care” for treatment. The Consonus Pharmacy team put together 6 things to know about Remdesivir. Click the link below to learn more.

Remdesivir use for COVID-19


April 17, 2020

Resources & Trainings

Consonus Pharmacy has a longstanding history of working together collaboratively with Oregon Care Partners (OCP) on developing curriculum and training caregivers. OCP and Relias are now offering free, unlimited access to relevant resources to help healthcare professionals and individuals prepare and prevent the spread of Coronavirus and Influenza. There are more than 130 free online classes available. Please help spread the word and share these resources with your network of caregivers, families and others who will benefit.


Important Update on Medication Supply

Media and public health authority reports are fueling concerns about the impact of COVID-19 on drug supply. We want you to know:

1. Consonus has not experienced any systemic, broad based negative impact on medication supply.

2. It is not necessary to “stock up” or make broad changes to your pharmacy ordering patterns at this time

April 16, 2020

Avoid Fraud Scams

The coronavirus pandemic has created a new epidemic of fraudsters and scammers, preying on the vulnerability of a public hungry for treatments, tests, personal protection equipment, and more. These schemers offer products that are unsafe, unproven, phony, and harmful, with no regard for public health and safety. It is important for pharmacists to be aware of these schemes and scams. Don’t unsuspectingly fall prey to these offers, and be armed with information to warn your patients. Awareness also helps you ask your patients targeted questions if they describe unexpected side effects from drugs or unexplained symptoms.

Read the update from APhA on Fraud Scams: Read Update



Consonus Pharmacy has updated the Hydroxychloroquine Facility Communication that was originally posted on April 2, 2020.

The updated version includes two new pieces of information:

  1. Diagnosis requirement
  2. AMDA recommendation/stance on use of hydroxychloroquine

Read the Hydroxychloroquine Facility Communication Update


April 7, 2020


“Our healthcare workers have been nothing short of heroes”.

Phil Fogg, CEO of Marquis Companies and Consonus Healthcare shares a new way you can support Healthcare Heroes who are working on the front lines during the COVID-19 pandemic. Watch the video!

To support #HealthcareHeroes, follow these steps:

1. Download your free #HealthcareHeroes printable here or purchase your own here
2. Find a place to proudly display the You Are Vital poster or sticker
3. Take a picture of yourself with it and post to social media


March 23, 2020

Important Update on Temporary Delivery Changes

Beginning March 24th, Consonus is making temporary adjustments to our delivery methods to maximize our Infection Prevention and Control efforts.  All deliveries from Consonus will be in disposable paper bags, no signature is required upon acceptance of delivery – the driver will simply record the name of the recipient, and returns will be sent in pharmacy provided plastic bags. More details provided in the link below.

Delivery Change


March 19, 2020

Q: Is there any evidence that NSAIDs (non-steroidal anti-inflammatory drugs), such as Ibuprofen, worsen COVID-19 if used to manage the symptoms of pain or fever?

A: No. The World Health Organization (WHO) clarified recent guidance on ibuprofen. There is currently no strong scientific evidence that ibuprofen, or other NSAIDs, can make COVID-19 worse.

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said, ““I have not seen any firm data to indicate there is a problem or prove there is not a problem”. He also said physicians widely believe acetaminophen (Tylenol) is best for reducing a fever, if that is the primary goal of the treatment.

NSAID use is often limited in the older population related to known side effects and risks (bleeding, peptic ulcer, increased blood pressure and kidney injury) that often outweigh the benefits. Current advice includes that these medicines are used at the lowest effective dose for the shortest possible period.

If your patient is already taking Ibuprofen, or another NSAID, to manage conditions such as rheumatoid arthritis or other chronic pain, we do not advise stopping out of concern about COVID-19.

As with all medication research in context of the pandemic, it is constantly evolving. If you have any questions around the use of NSAIDs or other medications, please contact your consultant pharmacist.


March 18, 2020

Q: Are there any approved treatments for COVID-19 today?

A: No. Some specific treatments are under investigation and will be tested through clinical trials. The World Health Organization is helping to accelerate research and development efforts with a range of partners. None of the investigational therapies are proven, but literature is evolving quickly. Currently, we do NOT recommend folding any of the investigational therapies into practice. Some of the options that are under investigation are:

  • Hydroxychloroquine (Plaquenil)/ Chloroquine– best known for its use in rheumatic diseases/malaria, being investigated for activity for coronaviruses
  • Antivirals (oseltamivir)– no antiviral drug has been proven to work against COVID-19 in humans, although many randomized controlled trials are ongoing
  • Remdesivir (GS-5734, RDV) -not FDA-approved and is available for investigational use only. It is a nucleotide analog antiviral
  • Corticosteroids– are not recommended as part of treatment for COVID-19 unless other indications exist
  • Nebulized bronchodilators- may risk spread of the virus, in general meter dose inhalers (MDIs) are preferred. Ask your pharmacist for guidance.
  • Antibiotics- are generally NOT recommended
  • Empiric neuraminidase (NMD) inhibitor- Data does not support use for COVID-19
  • HIV therapies-Lopinavir/ritonavir (Kaletra)- under investigation
  • Tocilizumab (Actemra) – inteurlukin-6 (IL-6) inhibitor being investigated for cytokine storm associated with severe COVID-19 disease
  • ACE-inhibitors/ ARBs (angiotensin-receptor blockers)- no experimental or clinical data demonstrating beneficial or adverse outcomes among COVID-19 patients using ACE-I or ARB medications

Resources for ongoing studies and drugs in the pipeline:

If you need additional information on these investigational therapies, please contact your Consultant Pharmacist.

March 17, 2020

Today’s update applies to Assisted Living Facility (ALF) Customers: 

We realize that in your community you may have several pharmacy providers that residents and families have chosen to work with. As your partner in the delivery of care we want to ensure that you know that we are here to help you and residents in times of need.  As more families become personally affected by COVID-19, their ability to obtain medications through their normal channels may be inhibited. If a resident uses another pharmacy and is unable to obtain medications in a timely manner related to delivery delays, we’re here to help.  We will waive all emergency delivery fees during this national crisis. Please review the Medication Management Preparedness Alert and FAQ for additional details.

COVID-19 Emergency Preparedness Medication Delivery

COVID-19 Emergency Prepardeness Medication FAQ


March 16, 2020

Consultant Pharmacist Visitation Update:

With the new guidance restricting visitor access to all facilities our consultants are leveraging technology to provide services remotely for our customers. To help prevent and control the spread of COVID19 we are eliminating all non-essential visits. Pharmacists will be completing MRR (medication regimen review) off-site using Electronic Health Records/MARs and participating in IDT meetings via teleconference or webinar options.

For communities that do not have remote chart access or paper charts, we will work with facility leadership on a plan to provide a modified service to ensure compliance with MRR regulations during this National State of Emergency. We understand the consultant services are essential to patient safety and we don’t want to lose focus on the importance of medication management in addition to infection control. In addition to the scheduled MRR, we will continue to provide admissions reviews (aMRRs) for SNFs and interim reviews (iMRR) on demand to meet patient needs.

Consultant Nurse Visitation Update:

In line with the pharmacist visitation policy, the nurse will also be leveraging technology to support you and your team. The goal of the nurse consultant team, is that there is no disruption to your normal consulting schedule. The Consonus Nurse Consultants are well versed in eHR’s and can assist with monitoring your health record, while you are focused on patient and resident care. The nurses are also available to do education via webinar and answer any questions related to pharmacy processes that you may need clarification on. Please don’t hesitate to reach out to your consultant team for any question and ideas on how they can support your patient care efforts.


March 12, 2020

Consonus Pharmacy’s Regional Director of Operations, Teri Ferriera, is a featured presenter in ASCP’s free webinar “COVID19: Latest Guidance from the Front Lines” on Friday, March 13th.

Hear from the Teri and other pharmacists and health professionals helping to care for some of the nursing facilities in Washington State and around the country already hit hard by the coronavirus.

Watch LIVE at 12:00pm ET on March 13 at or

There is NO pre-registration for this webinar.


March 10, 2020

Q: Do I need to notify the pharmacy if we have suspected or confirmed cases of COVID-19 within our facility?

A: Yes. Consonus Pharmacy is taking every precaution to reduce the spread of COVID-19. If you have a suspected or confirmed case, please reach out to your consultant nurse, pharmacist or call the pharmacy directly. Upon the receipt of this information Consonus Pharmacy will elevate the pharmacy infection control policy to Level 4, which includes more intensive precautionary steps in order to keep our patients and staff safe and our operations and customer facilities void of contaminants.

Q: Can the pharmacy provide COVID-19 Test Kits to clinicians?

A: No. The CDC indicates as availability of diagnostic testing for COVID-19 increases, clinicians will be able to access laboratory tests for diagnosing COVID-19 through clinical laboratories performing tests authorized by FDA under an Emergency Use Authorization (EUA). Clinicians will also be able to access laboratory testing through public health laboratories in their jurisdictions.

Q: Are there any antiviral medications recommended to prevent or treat COVID-19?

A: No. There are currently no antiviral drugs licensed by the U.S. Food and Drug Administration (FDA) to treat COVID-19.

However, those infected with the virus should receive appropriate care to relieve and treat symptoms, and those with severe illness should receive optimized supportive care. Some specific treatments are under investigation, and will be tested through clinical trials. World Health Organization is helping to accelerate research and development efforts with a range of partners.

The FDA is aggressively monitoring the market for any firms marketing products with fraudulent COVID-19 diagnosis, prevention or treatment claims. The FDA will use every authority at their disposal to protect consumers from bad actors who take advantage of a crisis to deceive the public. Refer to trusted sources for information, such as CDC, FDA, WHO or contact your pharmacist with questions.


March 4, 2020


Consonus Pharmacy is committed to keeping your staff and residents safe.  This Frequently Asked Questions update addresses common inquiries that we’ve been receiving regarding the impact of Coronavirus (COVID-19) on your pharmacy services.  The news is changing rapidly.  We will send new updates as conditions change.

Date:  Information based on status at 5 PM PST, March 4, 2020.

Q:  Do any of the sites served by Consonus currently have verified cases of COVID-19?

A:  No.

Q:  Will the pharmacy have a shortage of meds? How should we ensure meds are available?

A:  There are no indications that medication supplies will be negatively impacted at this time.

Consonus Pharmacy sources our medication supply through?Cardinal Health, one of the three largest distributors of medications in the U.S. We are in constant contact with their team as they monitor the impact of Coronavirus on the world’s drug supply chain. At present, there is no immediate direct threat to availability of medications. There are some raw material suppliers in the area of Wuhan, China, but the overall supply chain has not been negatively impacted. None of Cardinal’s generic products come from these sites. Cardinal has been proactively monitoring the situation for the last month, and they have worked with suppliers to secure additional safety stock. We will continue to monitor and will advise if the supply situation is impacted in any way.

Q:  I have families requesting a private purchase of a 1-month extra supply.? If we ask for costs and place an order on their behalf do you recommend this?

A:  Current conditions do not merit advance purchase of medication supply.

There have been advisories published in the media that recommend advance purchase, but those are aimed at members of the public not currently residing in care settings with medication management practices in place. We can accommodate this request if it is important for peace of mind to a resident, but it is not something we recommend at this time.

Q: Are any delays in pharmacy services anticipated? 

A: No delays in pharmacy services are expected at this time.  We remain fully staffed, and delivery services are operating on usual timelines.

Q: What safeguards are being put in place to ensure uninterrupted pharmacy service?

A: Consonus is equipped and staffed to sustain a 24-7 operation.  We have a full Emergency Preparedness plan in place and have initiated escalated hygiene practices to help prevent transmission of COVID-19.

Q: Will my Consulting Pharmacist or nurse visits be impacted?

A: Consultants who might pose a risk to facility staff and patients will not visit served facilities.  Ideally, we have remote access available to your EHR system in place and can continue full service without interruption.  If you would like to take further steps to arrange remote access, please contact your consultant to arrange.  The full policy is:

  • Consultants that are sick should not visit facilities and notify supervisor
  • Employees who have symptoms of acute respiratory illness (cough, shortness of breath, sore throat) are recommended to stay home and not come to work until they are free of fever (100.4° F [37.8° C] or greater using an oral thermometer), signs of a fever, and any other symptoms for at least 24 hours, without the use of fever-reducing medications
  • Consultants should refrain from visiting the buildings for non-essential reasons
  • Consultants should not work in facilities that are having a respiratory outbreak
  • Before visiting a facility, Consultants should contact facility leadership on the same day and ensure there are no respiratory outbreaks or surveillance for outbreaks
  • Consultants should monitor e-mails daily for pharmacy communication regarding infectious disease outbreaks in facilities
  • Before entering a building, Consultants should monitor for signs posted outside to notify the public of any respiratory outbreak
  • If consultants are working in a facility and become aware of documented respiratory outbreaks or surveillance for respiratory outbreaks, they should leave the facility and reschedule the work or complete remotely if possible
  • If consultants have the option, they should complete reviews remotely with electronic health records
  • Recommend technology to attend IDT meetings (zoom, webinar, conference calls)
  • If remote reviews are not an option and the review/meeting cannot be postponed, please contact your supervisor for guidance
  • Before consultants travel, they should check the CDC’s Traveler’s Health Notices for the latest guidance and recommendations and consult supervisor
  • Employees who are well but who have a sick family member at home with COVID-19 should notify their supervisor and refer to CDC guidance for how to conduct a risk assessment of their potential exposure.

Q: Can we purchase protective gear (PPE) (i.e. masks (surgical/procedural/N95, gloves) through your pharmacy?

A: Consonus does not currently have enough to distribute.  Those products are on allocation, which tends to lock supply down to existing business relationships.  Facilities should work closely with their current medical supply provider to maximize your allocation of PPE products.  Consonus will continue to effort through our industry contacts to secure PPE product, but none is available at this time.

Q: Can Consonus assist with the logistics of getting staff fitted for N95 masks?

A: Consonus does not provide N95 mask fit testing services.  However, our research has found that many area hospital systems offer this service as part of their Occupational Health service. While some of these hospital systems only provide this service to staff, many have opened their doors to outside companies for fit testing services.

Additionally, many private companies, such as Concentra, have locations found throughout the Consonus footprint and are willing to schedule these services after connecting with their team.

Q: What additional steps is Consonus taking to reduce the likelihood of transmission between the pharmacy and facility?

A: Consonus escalated to Level 2 in our Hygiene Policy.  That policy focuses on practices in the pharmacy and our direct interactions with facility and community staff and patients.  All steps in that policy are designed to reduce the likelihood of transmission of infectious agents between the pharmacy and all points of service.  Level 2 practices include delivery drivers with PPE gloves that will be disposed after each delivery drop, and tote cleaning procedures to disinfect returned pharmacy totes.  We recommend that e kits and Cubex cubies remain in the medication room when not in transport to and from your facility.

Care facilities should be diligent about executing your internal infection control policies and engage in thorough communication with your staff to gain adherence to basic hygiene practices recommended by the CDC.

Q: Do we need to proactively get providers orders?

A: Continue to follow standard practices for managing medication orders.

Q: What can we focus on to reduce the chance of Emergency Room visits?

A: Reducing the chance of Emergency Room visits can prevent bringing illnesses back to the community.

  • Confirm that you have a COVID-19 Admission Policy based on current guidance from CDC, Health Department, and AMDA Guidelines
  • Review if your providers have a Physician/NP provider decision-making protocol or tool for SNF/ICF, ALF and residential patients with COVID-19
  • Follow protocols from CDC, DHS, and ACHA for best practices for preventing the spread of the COVID-19. Be in close contact with your local and state health department and monitor the CDC COVID-19 website for the latest information as public health guidance will shift as the outbreak evolves.


March 3, 2020

Consonus Pharmacy sources all our medication supply through Cardinal Health, one of the three largest distributors of medications in the U.S. We are in constant contact with their team as they monitor the impact of Coronavirus on the world’s drug supply chain. At present, there is no immediate direct threat to availability of medications. There are some raw material suppliers in the area of Wuhan, China, but the overall supply chain has not been negatively impacted. None of Cardinal’s generic products come from these sites. Cardinal has been proactively monitoring the situation for the last month, and they have worked with suppliers to secure additional safety stock. We will continue to monitor and will advise if the supply situation is impacted in any way.